Kingstone Capital Partners Texas LLC Takes $14.52 Million Position in Abbott Laboratories $ABT

Key Points

• Kingstone Capital Partners Texas LLC has acquired a new stake in Abbott Laboratories, purchasing 106,740 shares valued at approximately $14.5 million.
• Abbott reported a quarterly revenue of $11.14 billion and earnings per share (EPS) of $1.26, meeting analyst expectations, while raising its FY 2025 EPS guidance.
• Each stockholder will receive a quarterly dividend of $0.59 per share, with the dividend payout ratio at 29.57%, reflecting a yield of 1.7%.

Kingstone Capital Partners Texas LLC acquired a new stake in Abbott Laboratories (NYSE:ABT - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 106,740 shares of the healthcare product maker's stock, valued at approximately $14,518,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Cim LLC grew its position in shares of Abbott Laboratories by 0.4% in the 4th quarter. Cim LLC now owns 16,967 shares of the healthcare product maker's stock valued at $1,919,000 after acquiring an additional 73 shares during the period. Consilium Wealth Advisory LLC raised its position in shares of Abbott Laboratories by 2.1% in the 1st quarter. Consilium Wealth Advisory LLC now owns 3,822 shares of the healthcare product maker's stock valued at $507,000 after buying an additional 78 shares in the last quarter. Mayflower Financial Advisors LLC increased its position in Abbott Laboratories by 0.5% during the 1st quarter. Mayflower Financial Advisors LLC now owns 17,327 shares of the healthcare product maker's stock worth $2,298,000 after purchasing an additional 78 shares in the last quarter. FF Advisors LLC increased its position in Abbott Laboratories by 4.3% in the 2nd quarter. FF Advisors LLC now owns 1,904 shares of the healthcare product maker's stock valued at $259,000 after acquiring an additional 79 shares during the period. Finally, Opes Wealth Management LLC boosted its stake in shares of Abbott Laboratories by 2.9% in the 1st quarter. Opes Wealth Management LLC now owns 2,854 shares of the healthcare product maker's stock valued at $379,000 after purchasing an additional 80 shares during the last quarter. Institutional investors own 75.18% of the company's stock.

Abbott Laboratories Stock Performance

Abbott Laboratories stock traded down $0.59 during mid-day trading on Tuesday, hitting $136.03. The company had a trading volume of 2,826,996 shares, compared to its average volume of 6,637,250. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25. The company has a market capitalization of $236.76 billion, a price-to-earnings ratio of 17.04, a P/E/G ratio of 2.58 and a beta of 0.69. The company's fifty day moving average is $130.56 and its 200-day moving average is $131.11. Abbott Laboratories has a 12-month low of $110.86 and a 12-month high of $141.23.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, hitting the consensus estimate of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The business had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.01 billion. During the same period in the prior year, the company posted $1.14 EPS. The business's quarterly revenue was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Equities research analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be issued a $0.59 dividend. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.7%. Abbott Laboratories's payout ratio is presently 29.57%.

Insider Activity

In related news, CFO Philip P. Boudreau sold 5,550 shares of the company's stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the transaction, the chief financial officer owned 51,003 shares of the company's stock, valued at $6,862,453.65. This represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.46% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Leerink Partners initiated coverage on shares of Abbott Laboratories in a research note on Monday, June 16th. They issued a "market perform" rating and a $143.00 price objective on the stock. Leerink Partnrs upgraded shares of Abbott Laboratories to a "hold" rating in a report on Monday, June 16th. Raymond James Financial reduced their target price on shares of Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating for the company in a research note on Friday, July 18th. Evercore ISI boosted their price objective on shares of Abbott Laboratories from $140.00 to $145.00 and gave the company an "outperform" rating in a research note on Tuesday, July 8th. Finally, Jefferies Financial Group raised shares of Abbott Laboratories from a "hold" rating to a "buy" rating and boosted their price objective for the company from $143.00 to $145.00 in a research note on Friday, July 18th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $145.22.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.